ES2524645A1 - Oral formulation for the treatment of cardiovascular diseases (Machine-translation by Google Translate, not legally binding) - Google Patents

Oral formulation for the treatment of cardiovascular diseases (Machine-translation by Google Translate, not legally binding) Download PDF

Info

Publication number
ES2524645A1
ES2524645A1 ES201330841A ES201330841A ES2524645A1 ES 2524645 A1 ES2524645 A1 ES 2524645A1 ES 201330841 A ES201330841 A ES 201330841A ES 201330841 A ES201330841 A ES 201330841A ES 2524645 A1 ES2524645 A1 ES 2524645A1
Authority
ES
Spain
Prior art keywords
translation
treatment
machine
legally binding
google translate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201330841A
Other languages
Spanish (es)
Other versions
ES2524645B1 (en
Inventor
Pablo MARTÍN SANZ
Javier URBANO HURTADO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrer Internacional SA
Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III
Original Assignee
Ferrer Internacional SA
Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Internacional SA, Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III filed Critical Ferrer Internacional SA
Priority to ES201330841A priority Critical patent/ES2524645B1/en
Publication of ES2524645A1 publication Critical patent/ES2524645A1/en
Application granted granted Critical
Publication of ES2524645B1 publication Critical patent/ES2524645B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Abstract

The present invention relates to the use of a pharmaceutical composition that includes an inhibitor of hmg-coa reductase, in particular, a statin and acetylsalicylic acid in a manner that minimizes the interaction of acetylsalicylic acid with statin, for the prevention or treatment of cardiovascular diseases. (Machine-translation by Google Translate, not legally binding)

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

imagen17image17

imagen18image18

imagen19image19

imagen20image20

imagen21image21

imagen22image22

imagen23image23

imagen24image24

imagen25image25

imagen26image26

P201330841 05-11-2013 P201330841 11-05-2013

Condiciones de la prueba de disolución: Aparato: USP 1 (cesto) Velocidad de agitación: 100 rpm Dissolution test conditions: Device: USP 1 (basket) Stirring speed: 100 rpm

5 Volumen de disolución: 900 ml Medio de disolución: tampón fosfato a pH 6,8 5 Solution volume: 900 ml Dissolution medium: phosphate buffer at pH 6.8

Los resultados (tabla 11 y figura 5) fueron los siguientes: The results (table 11 and figure 5) were the following:

10 Tabla 11: resultados de disolución de % de AAS disuelto en cápsulas de AAR 10 Table 11: dissolution results of% of ASA dissolved in AAR capsules

Cápsula de AAR AAR capsule

Tiempo (min) Time (min)
% de AAS disuelto % of dissolved AAS

0 0
0 0

15 fifteen
73,1 73.1

20 twenty
86,2 86.2

30 30
95,3 95.3

45 Four. Five
97,3 97.3

Como se muestra en la tabla 10 y la tabla 11, la cápsula de AAR que contenía comprimidos de AAS de 50 mg x2 recubiertos con película, que comprendían un recubrimiento de comprimido de 8,7 mg/cm2, muestra valores medios superiores al As shown in Table 10 and Table 11, the AAR capsule containing 50 mg x2 film-coated AAS tablets, comprising a tablet coating of 8.7 mg / cm2, shows average values greater than

15 80 % a los 15 minutos en el caso de pH 4,5 y próximos al 75 % a pH 6,8. 15 80% at 15 minutes in the case of pH 4.5 and close to 75% at pH 6.8.

Una formulación que comprende comprimidos de AAS con un recubrimiento de 8,7 mg/cm2 proporciona más protección y aislamiento al comprimido de ácido acetilsalicílico, haciendo más difícil que el ácido salicílico sublime y desencadene la A formulation comprising ASA tablets with a coating of 8.7 mg / cm2 provides more protection and isolation to the acetylsalicylic acid tablet, making it more difficult for sublime salicylic acid to trigger

20 degradación de los demás componentes, en particular, de la atorvastatina o la rosuvastatina, dentro de la cápsula final. Degradation of the other components, in particular, of atorvastatin or rosuvastatin, within the final capsule.

imagen27image27

Claims (1)

imagen1image 1 imagen2image2 imagen3image3 imagen4image4
ES201330841A 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases Active ES2524645B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201330841A ES2524645B1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330841A ES2524645B1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
ES2524645A1 true ES2524645A1 (en) 2014-12-10
ES2524645B1 ES2524645B1 (en) 2015-12-02

Family

ID=52004086

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330841A Active ES2524645B1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases

Country Status (1)

Country Link
ES (1) ES2524645B1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307463T1 (en) * 2001-08-28 2008-12-01 Longwood Pharmaceutical Research, Inc. COMBINATION DOSAGE FORM CONTAINING A CHOLESTEROL REDUCING AGENT, A RENIN-ANGIOTENSIN INHIBITOR, AND AN ASPIRINE.
WO2012002919A1 (en) * 2010-06-30 2012-01-05 Mahmut Bilgic Pharmaceutical formulations comprising atorvastatin and aspirin
WO2012081905A2 (en) * 2010-12-17 2012-06-21 Hanmi Holdings Co. , Ltd. Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin
WO2012124973A2 (en) * 2011-03-15 2012-09-20 Boryung Pharmaceutical Co., Ltd Combined formulation with improved stability

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307463T1 (en) * 2001-08-28 2008-12-01 Longwood Pharmaceutical Research, Inc. COMBINATION DOSAGE FORM CONTAINING A CHOLESTEROL REDUCING AGENT, A RENIN-ANGIOTENSIN INHIBITOR, AND AN ASPIRINE.
WO2012002919A1 (en) * 2010-06-30 2012-01-05 Mahmut Bilgic Pharmaceutical formulations comprising atorvastatin and aspirin
WO2012081905A2 (en) * 2010-12-17 2012-06-21 Hanmi Holdings Co. , Ltd. Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin
WO2012124973A2 (en) * 2011-03-15 2012-09-20 Boryung Pharmaceutical Co., Ltd Combined formulation with improved stability

Also Published As

Publication number Publication date
ES2524645B1 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
BRPI0606883A2 (en) pharmaceutical composition for oral administration, method for preparing a tablet, and single solid dosage form
FI2508188T3 (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
GT201000275A (en) CAPSULE FOR THE PREVENTION OF CARDIOVASCULAR DISEASES
DOP2012000264A (en) PHARMACEUTICAL FORMULATION IN THE FORM OF TWO-COATED TABLETS THAT INCLUDE INHIBITOR OF HMG-COA REDUCTASA AND IRBESARTAN
CO7350622A2 (en) Formulation of a compound pharmaceutical capsule comprising irbesartan and hmg-coa reductase inhibitor
CL2015003561A1 (en) Pharmaceutical composition for oral administration for use in the prevention and / or treatment of cardiovascular disease.
PH12017500269A1 (en) Composite formulation for oral administration comprising omega-3 fatty acid esters and statins
ES2524645A1 (en) Oral formulation for the treatment of cardiovascular diseases (Machine-translation by Google Translate, not legally binding)
TH160994A (en) An oral formulation for the treatment of heart disease and circulatory system. (Cardiovascular Diseases)
TH160994B (en) Oral formulation for the treatment of heart disease and circulatory system (Cardiovascular Diseases)
TH126521A (en) A pharmaceutical formulation in a two-layer tablet formulation that includes: HMG-COA Reductase Inhibitor and Urbesar Tan
RU2014105690A (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING STATIN
PL400338A1 (en) Solid oral dosage form comprising sunitinib L-malate
TH133918A (en) Oral complex consisting of omega-3 fatty acid esters And an HMG-COA reductase inhibitor
AR097023A1 (en) COMPOSITION FOR THE MANAGEMENT OF NAUSE AND VOMITS, METHOD FOR RELIEFING THEM, PHARMACEUTICAL DOSAGE SYSTEM
DOP2008000034A (en) PHARMACEUTICAL FORMULATION THAT INCLUDES SIMVASTATIN AND EZETIMIBE
TH133918B (en) Oral complex consisting of omega-3 fatty acid esters And an HMG-COA reductase inhibitor
IN2013MU03765A (en)
TN2010000445A1 (en) Oral and injectable formulations of tetracycline compounds
EA201400740A1 (en) PHARMACEUTICAL COMPOSITIONS OF SEVELAMERA

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2524645

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20151202